Epkinly monotherapy achieved a 67% ORR and 43% CR rate in the expansion cohort of heavily pretreated CLL patients. The C1 OPT cohort showed a 60% ORR, with reduced CRS severity through optimized ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved ...
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ...
Please provide your email address to receive an email when new articles are posted on . 61% of patients with heavily pretreated CLL responded to single-agent epcoritamab therapy. Researchers intend to ...
ASH 2024 will focus on early intervention with advanced therapies, including CLL and SMM treatment trials. Pediatric B-ALL treatment with blinatumomab and quality of life improvements in CLL will be ...
LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States and ranked among the nation’s top 5 cancer centers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results